Standard Newswire is a cost-effective and efficient newswire service for public policy groups, government agencies, PR firms, think-tanks, watchdog groups, advocacy groups, coalitions, foundations, colleges, universities, activists, politicians, and candidates to distribute their press releases to journalists who truly want to hear from them.

Do not settle for an email blasting service or a newswire overloaded with financial statements. Standard Newswire gets your news into the hands of working journalists, broadcast hosts, and news producers.

Find out how you can start using Standard Newswire to

CONNECT WITH THE WORLD

VIEW ALL Our News Outlets
Sign Up to Receive Press Releases:

Standard Newswire™ LLC
209 W. 29th Street, Suite 6202
New York, NY 10001, USA.
(212) 290-1585

USAID Awards Grants for Development of New Tuberculosis Drugs, Diagnostics, and Management Approaches

Contact: Press Office, U.S. Agency for International Development (USAID), 202-712-4320; Public Information: 202-712-4810

WASHINGTON, Oct. 15 /Standard Newswire/ -- The U.S. Agency for International Development (USAID) is pleased to announce new grants to The Global Alliance for TB Drug Development and the International Union Against TB and Lung Disease. These grants will support late stage clinical trials for new drugs, diagnostics, and approaches to improve detection and management of tuberculosis (TB), TB/HIV, and drug resistant TB.

More than one-third of the world's population is infected with the TB bacterium, and nearly 1.7 million people die from the disease every year. Rapid and accurate diagnosis of TB is notoriously difficult, and TB treatment is long and challenging for both patients and their families.

The grant to the Global Alliance for TB Drug Development will support late-stage clinical trials for new drugs that offer the potential to shorten the duration of TB treatment, to work against drug-resistant TB, and to be safely administered with anti-retrovirals to people with HIV/AIDS. USAID has committed $3 million for the first year of this grant, and the total funding over five years could reach up to $40 million.

The grant to the International Union Against TB and Lung Disease will focus on field evaluations of diagnostic techniques for TB, clinical trials and operations research to improve patient management and treatment efficacy, and infection control measures for TB and multi-drug resistant TB. This grant will emphasize the translation of research results into global and national policy. USAID has committed $3.7 million for the first year, and the total award over five years could reach up to $80 million.

"Tuberculosis remains a major public health threat," said Dr. Kent Hill, USAID's Assistant Administrator for Global Health. "New tools are urgently needed to combat this scourge, and USAID is committed to bringing new tools to the field, including drugs, diagnostics, and improved approaches to manage the disease, including multi-drug resistant and extensively drug resistant TB."

USAID is the largest single-country bilateral donor for TB; since 1998, it has provided more than $777 million to global TB control programs. USAID currently assists TB programs in 40 countries provided approximately $162 million of FY 2008 funds to support international TB control efforts and research activities.

For more information about USAID and its global health programs, please visit www.usaid.gov.